BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06987513 (Pemvidutide in Alcohol Use Disorder): BVCT ex-ante prediction vs. reported outcome

On 13 Jun 2026, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 28 Jul 2026 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (superior to SoC naltrexone in HDD/week).

Clinical Trial

NCTID
NCT06987513
Acronym
RECLAIM
Drug Name
Pemvidutide
Drug MoA
GLP1R/GCGR dual agonist
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Mental Disorders
Indication
Alcohol Use Disorder (AUD)
Human Patients
100
Sponsor
Altimmune
Phase
Phase 2

Prediction of , index 2146

Prospective Prediction
Prediction Index
2146
Prediction Date
Commercial Prediction
partial SUCCESS (commercially sufficient yet moderate clinical benefit in reducing heavy drinking days per week slightly superior to naltrexone with RR < 0.8, slightly inferior to tirzepatide with RR > 1.2, moderately inferior to retatrutide with RR > 1.4)
Technical Prediction
SUCCESS (statistically significant clinical benefit in reducing heavy drinking days per week compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
45 days in advance
Readout Data Interpretation
pemvidutide met the primary endpoint by achieving a placebo-adjusted reduction of 1.45 heavy drinking days per week (P = 0.0014), which is superior to the placebo-adjusted reduction of 0.3 heavy drinking days per week achieved by naltrexone (1.2 days per month, see add'l link below) with RR = 0.21 (0.3/1.45), and superior to the placebo-adjusted reduction of 1.0 heavy drinking days per week achieved by semaglutide (14.7 % x 7 days, 10.1016/S0140-6736(26)00305-3) with RR = 0.69 (1/1.45); tirzepatide on AUD trial is ongoing and retatrutide on AUD may be planned, pending for future readout
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (superior to SoC naltrexone in HDD/week)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Phase
Phase 2
Status
Completed
Enrollment
100
Lead sponsor
Altimmune, Inc.
Conditions
Alcohol Use Disorder (AUD)
Interventions
DRUG: Pemvidutide; OTHER: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2025-05-15
Primary completion
2026-07-30
Completion
2026-07-30
Primary outcomes
  • Change from baseline in the average number of heavy drinking days per week (Baseline to Weeks 21-24)

NCT06987513 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials